PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

被引:86
|
作者
Li, Qian [1 ]
Han, Jingjing [1 ]
Yang, Yonglin [2 ]
Chen, Yu [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Nanjing, Peoples R China
[2] Nanjing Med Univ, Affiliated Taizhou Peoples Hosp, Dept Infect Dis, Taizhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
PD-1; inhibitor; PD-L1; hepatocellular carcinoma; immune checkpoint; tumor immune escape; immunotherapy; REGULATORY T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; TREMELIMUMAB PLUS DURVALUMAB; PD-1; BLOCKADE; OPEN-LABEL; CANCER; EXPRESSION; SORAFENIB; THERAPY; MECHANISMS;
D O I
10.3389/fimmu.2022.1070961
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a long time, but there are still many shortcomings. In recent years, with the deepening of research on tumor immune microenvironment, researchers have begun to explore new approaches in immunotherapy, and the introduction of immune checkpoint inhibitors has brought fundamental changes to the treatment of HCC. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that plays an important role in down-regulating immune system function and promoting tolerance. Programmed cell death ligand 1 (PDL-1) is involved in tumor immune evasion by binding to PD-1, resulting in failure of treatment. Currently, immunotherapy targeting the PD-1/PD-L1 axis has achieved unprecedented success in HCC, but it also faces great challenges, with its low remission rate still to be solved. For most patients with HCC, the PD-1/PD-L1 pathway is not the only rate limiting factor of antitumor immunity, and blocking only the PD-1/PD-L1 axis is not enough to stimulate an effective antitumor immune response; thus, combination therapy may be a better option. In this study, changes in the immune microenvironment of HCC patients were reviewed to clarify the feasibility of anti-PD-1/PD-L1 therapy, and a series of monotherapy and combination therapy clinical trials were summarized to verify the safety and efficacy of this newly developed treatment in patients with advanced HCC. Furthermore, we focused on hyperprogressive disease and drug resistance to gain a better understanding of PD-1/PD-L1 blockade as a promising treatment.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
    Zhao, Yanan
    Wu, Di
    Yao, Quanjun
    Yuan, Hang
    Hu, Hongtao
    Li, Hailiang
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 49 (02) : 147 - 154
  • [42] Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Wen Wen
    Yong Zhang
    Hua Zhang
    Yingshuang Chen
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 969 - 978
  • [43] Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma
    Wang, Jiting
    Li, Jun
    Tang, Guiju
    Tian, Yuan
    Su, Song
    Li, Yaling
    ONCOLOGY LETTERS, 2021, 21 (04) : 1 - 8
  • [44] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
    Wang, Dongxu
    Lin, Jianzhen
    Yang, Xu
    Long, Junyu
    Bai, Yi
    Yang, Xiaobo
    Mao, Yilei
    Sang, Xinting
    Seery, Samuel
    Zhao, Haitao
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [45] ENHANCING CANCER CARE WITH IMPROVED CHECKPOINT INHIBITORS: A FOCUS ON PD-1/PD-L1
    Vickram, As
    Shofia, Saghya Infant
    Saravanan, A.
    Sivakumar, Vidhya Lakshmi
    Thamarai, Packiyam
    Sivasubramanian, Manikandan
    Chopra, Shivani
    Chopra, Hitesh
    EXCLI JOURNAL, 2024, 23 : 1303 - 1326
  • [46] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
    Dongxu Wang
    Jianzhen Lin
    Xu Yang
    Junyu Long
    Yi Bai
    Xiaobo Yang
    Yilei Mao
    Xinting Sang
    Samuel Seery
    Haitao Zhao
    Journal of Hematology & Oncology, 12
  • [47] Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
    Aden, Durre
    Zaheer, Samreen
    Sureka, Niti
    Trisal, Monal
    Chaurasia, Jai Kumar
    Zaheer, Sufian
    PATHOLOGY RESEARCH AND PRACTICE, 2025, 269
  • [48] Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors
    Sadal Refae
    Jocelyn Gal
    Nathalie Ebran
    Josiane Otto
    Delphine Borchiellini
    Frederic Peyrade
    Emmanuel Chamorey
    Patrick Brest
    Gérard Milano
    Esma Saada-Bouzid
    Investigational New Drugs, 2020, 38 : 160 - 171
  • [49] Covalent small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint
    Maslanka, A.
    Kitel, R.
    Konopka, J.
    Skalniak, L.
    FEBS OPEN BIO, 2024, 14 : 329 - 330
  • [50] PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
    Caccese, Mario
    Indraccolo, Stefano
    Zagonel, Vittorina
    Lombardi, Giuseppe
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 135 : 128 - 134